BACPHAR.BO · BSE
BACIL PHARMA LTD.
₹23.95
+2.44% (+₹0.57)
Prev. close
₹23.38
Volume
0
As of
BSE · may be slightly delayed · 16:00 IST
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About BACIL PHARMA LTD.
Bacil Pharma Limited develops, manufactures, and distributes pharmaceuticals products in India. The company offers tablets, capsules, injectables, ointments, and specialty products. Bacil Pharma Limited was incorporated in 1987 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Ganpat Dhondu Salekar
Headquarters
Mumbai
Employees
2
Website
bacilpharma.co.inExchange
View on BSE ↗Key stats
Market cap
₹33.56 Cr
P/E ratio (TTM)
27.5
EPS (TTM)
₹0.85
Beta (1Y · daily vs NIFTY 50)
0.22
Beta (5Y · monthly vs NIFTY 50)
-0.01
Shares float
60.58 L
EPS · quarter ended Jun 2026
₹0.22
Financial Performance
01 · Financials
FY22 growth needs FY21 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ₹5.80 L | ₹11.50 L | ₹13.10 L | ₹66.10 L | ₹0 | |
| EBITDA | — | ₹-9.78 L | ₹-5.63 L | ₹40.87 L | ₹99.00 L |
| ₹-3.86 Cr | ₹-10.20 L | ₹-5.90 L | ₹40.50 L | ₹99.00 L | |
| Diluted EPS | ₹-6.55 | ₹-0.17 | ₹-0.1 | ₹0.64 | ₹1.11 |
EBITDA, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹1.13 Cr | ₹1.33 Cr | ₹25.60 Cr | ₹27.39 Cr | |
| — | ₹2.06 L | ₹9.84 L | ₹16.39 L | ₹0 | |
| Stockholders' equity | — | ₹1.10 Cr | ₹1.21 Cr | ₹25.43 Cr | ₹24.81 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹-14.75 L | ₹-29,000 | ₹40.08 L | ₹71.16 L | |
| Investing cash flow | — | ₹-11.63 L | ₹7.84 L | ₹33.67 L | ₹-2.38 Cr |
| Financing cash flow | — | ₹6.28 L | ₹-6.28 L | ₹2.08 Cr | ₹-61.88 L |
| End cash position | — | ₹2.88 L | ₹4.15 L | ₹2.86 Cr | ₹56.85 L |
Operating cash flow, Change in working capital, Investing cash flow, Financing cash flow, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.49 L Cr | ₹9,410.5 | 84.7 | 14.85 | 15.3% | 0.00 | +12.3% | +51.8% |
| Torrent Pharmaceuticals Limited | ₹1.84 L Cr | ₹4,970 | 77.5 | 21.95 | 25.8% | 1.79 | +21.5% | +36.9% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹691.45 | 179.0 | 13.55 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,161 | 25.8 | 4.27 | 18.6% | 0.46 | +18.4% | +11.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,006.5 | 99.3 | 20.57 | 16.8% | 0.48 | +22.0% | +122.0% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Manipal Health Enterprises Limited | ₹99,047.90 Cr | ₹746.1 | 152.1 | 11.75 | 7.8% | 1.53 | +18.0% | — |
| Dr. Reddy's Laboratories Limited | ₹98,709.15 Cr | ₹1,198.3 | 29.8 | 2.62 | 11.4% | 0.21 | +3.2% | -9.3% |
| BACIL PHARMA LTD. | ₹32.19 Cr | ₹22.43 | 26.4 | 1.30 | 6.3% | 0.00 | — | -40.7% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 26
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.